IBTK and cancer: Moreover, CRISPR/Cas9-mediated KO (Figure 2—figure supplement 1A-C) or shRNA-mediated KD of IBTK in multiple cancer cell lines did not alter the levels of eIF4A1/2/3 (Figure 2B and C).